A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Registration Number
- NCT03845517
- Lead Sponsor
- Pfizer
- Brief Summary
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 350
- Male and/or female subjects between ≥18 and ≤75 years of age inclusive.
- Diagnosis of moderate to severe active Lupus.
- Receiving a stable dose of methotrexate, azathioprine, leflunomide, mizoribine, mycophenolate/mycophenolic acid, anti-malarials or corticosteroids.
- Active renal lupus
- Severe active central nervous system (CNS) lupus
- Have cancer or a history of cancer within 5 years of screening.
- Have a history of thrombosis (venous or arterial) or other vascular complications within the last 6 months, or any history of either recurrent thrombosis or a pulmonary embolus.
- Active bacterial, viral, fungal, mycobacterial or other infections
- Psychiatric condition including recent or active suicidal ideation or behavior
- Have active fibromyalgia/myofascial/chronic pain.
- Pregnant female subjects; breastfeeding female subjects; females subjects planning to become pregnant during the study; fertile male subjects and WOCBP who are unwilling or unable to use a highly effective method of contraception.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-06700841 30 mg PF-06700841 30 mg PF-06700841 30 mg PF-06700841 45 mg PF-06700841 45 mg PF-06700841 45 mg Placebo Placebo Placebo PF-06700841 15 mg PF-06700841 15 mg PF-06700841 15 mg
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52 Week 52 SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point increase) in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52 Week 52 BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline 12 Weeks prior at Week 52 (Week 40 to Week 52) In this outcome measure data is reported for participants who achieved a reduction in SRI-4 response with prednisone dose reduced to \<=7.5 mg/day and sustained for 12 weeks at Week 52.
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52 Week 52 LLDAS was defined as SLE disease activity index (SLEDAI-2k \<=4, with no activity in major organ systems \[renal, central nervous system, cardiopulmonary, vasculitis, fever\]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity) \<=1; a current prednisolone (or equivalent) dose \<=7.5 milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline Week 52 for achieving reduction in dose along with Week 40 to Week 52 for sustained dosing In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to \<=7.5 mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52).
Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10 Week 52 CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).
Change From Baseline in Planning Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Incidence Rate of Severe Flare Event Week 52 Incidence rate was defined as the number of new events per 100 person-years.
Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52 Baseline, Week 52 The FACIT-F Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).
Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Pain Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52 Baseline, Week 52 The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Number of Participants With Treatment-Emergent Adverse Events (AE) Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs.
Number of Participants With Serious Adverse Events (SAEs) Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Number of Participants With Adverse Events Leading to Discontinuation From Study Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this outcome measure, participants with adverse events leading to discontinuation from study were reported.
Number of Participants With Clinically Significant Vital Signs Abnormalities Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator.
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) Clinical significance in ECG abnormalities was judged by investigator.
Number of Participants With Laboratory Test Abnormalities Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks) Hematology (Hemoglobin\[hgb\], hematocrit, erythrocytes\[ery\]:\<0.8\*lower limit of normal\[LLN\];reticulocytes, reticulocytes/ery:\<0.5\*LLN,\>1.5\*upper LN\[ULN\];ery mean corpuscular volume\[EMC\], EMC hgb:\<0.9\*LLN,\>1.5\*ULN;EMC hgb concentration:\<0.9\* LLN;platelet:\<0.5\*LLN;leukocytes\[leu\]:\<0.6\*LLN,\>1.5\*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:\<0.8\* LLN,\>1.2\*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:\>1.2\*ULN;activated partial thromboplastin time\[PTT\], PTT, prothrombin time:\>1.1\*ULN);Clinical chemistry (Total/direct/indirect bilirubin, glucose-fasting:\>1.5\*ULN; aspartate aminotransferase\[AT\], alanine AT:\>3.0\*ULN; protein, albumin, HDL cholesterol:\<0.8\*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:\>1.3\*ULN;urate, LDL cholesterol:\>1.2\*ULN;potassium:\<0.9\*LLN,\>1.1\*ULN;calcium, bicarbonate:\<0.9\*LLN;creatine kinase:\>2.0\*ULN);Urinalysis (pH\<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase, granular/hyaline/WBCs casts:\>1).
Trial Locations
- Locations (157)
Stamford Therapeutics Consortium
🇺🇸Stamford, Connecticut, United States
Institute of Arthritis Research
🇺🇸Idaho Falls, Idaho, United States
Northshore University Hospital
🇺🇸Manhasset, New York, United States
UAB Hospital-Clinical Research Unit (CRU)
🇺🇸Birmingham, Alabama, United States
Arthritis and Osteoporosis Medical Center
🇺🇸La Palma, California, United States
Arthritis & Rheumatology Center of Oklahoma PLLC
🇺🇸Oklahoma City, Oklahoma, United States
The Kirklin Clinic
🇺🇸Birmingham, Alabama, United States
UAB Department of Medicine Clinical Research Enterprise
🇺🇸Birmingham, Alabama, United States
UAB Hospital Department of Pharmacy
🇺🇸Birmingham, Alabama, United States
Advanced Medical Research, LLC
🇺🇸La Palma, California, United States
East Bay Rheumatology Medical Group, Inc.
🇺🇸San Leandro, California, United States
Innovative health Research
🇺🇸Las Vegas, Nevada, United States
Accurate Clinical Research
🇺🇸Houston, Texas, United States
Clinical Research of West Florida
🇺🇸Tampa, Florida, United States
AdventHealth Tampa
🇺🇸Tampa, Florida, United States
Rose Radiology dba Akumin Inc.
🇺🇸Tampa, Florida, United States
Akumin Inc.
🇺🇸Tampa, Florida, United States
New England Research Associates, LLC
🇺🇸Bridgeport, Connecticut, United States
State Institution National Scientific Center "M.D. Strazhesko Institute of Cardiology" of National
🇺🇦Kyiv, Ukraine
The University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Multifield Medical Center of Odesa National Medical University
🇺🇦Odesa, Ukraine
St. Joseph Heritage Healthcare
🇺🇸Fullerton, California, United States
Desert Medical Advances
🇺🇸Palm Desert, California, United States
Inland Rheumatology and Osteoporosis Medical Group
🇺🇸Upland, California, United States
Millennium Clinical Trials
🇺🇸Thousand Oaks, California, United States
Inland Rheumatology Clinical Trials, Inc.
🇺🇸Upland, California, United States
New England Research Associates
🇺🇸Bridgeport, Connecticut, United States
Private Practice of Robert W. Levin
🇺🇸Clearwater, Florida, United States
SIMEDHealth, LLC Attn: Rheumatology
🇺🇸Gainesville, Florida, United States
SIMEDHealth, LLC
🇺🇸Gainesville, Florida, United States
Akumin, Inc
🇺🇸Palm Harbor, Florida, United States
Jefrey D. Lieberman, M.D., P.C.
🇺🇸Decatur, Georgia, United States
Atlanta Research Center for Rheumatology
🇺🇸Marietta, Georgia, United States
West Broward Rheumatology Associates, Inc
🇺🇸Tamarac, Florida, United States
Akumin Inc
🇺🇸Saint Petersburg, Florida, United States
Investigational Drug Services University of Kansas Hospital
🇺🇸Kansas City, Kansas, United States
The University of Kansas Hospital
🇺🇸Kansas City, Kansas, United States
Ochsner Clinic Foundation, Baton Rouge
🇺🇸Baton Rouge, Louisiana, United States
University of Michigan Brighton Center for Specialty Care
🇺🇸Brighton, Michigan, United States
Feinstein Institute for Medical Research
🇺🇸Manhasset, New York, United States
St. Lawrence Health System
🇺🇸Potsdam, New York, United States
Columbia University Medical Center.
🇺🇸New York, New York, United States
NYU Langone Ambulatory Care Brooklyn Heights
🇺🇸Brooklyn, New York, United States
Joint and Muscle Research Institute
🇺🇸Charlotte, North Carolina, United States
Irving Institute for Clinical and Transitional Research
🇺🇸New York, New York, United States
Gupta, Ramesh C MD
🇺🇸Memphis, Tennessee, United States
West Tennessee Research Institute
🇺🇸Jackson, Tennessee, United States
Rheumatic Disease Clinical Research Center, LLC
🇺🇸Houston, Texas, United States
Accurate Clinical Management, LLC
🇺🇸Baytown, Texas, United States
Arthritis Clinic of Central Texas
🇺🇸San Marcos, Texas, United States
Arthritis Northwest, PLLC
🇺🇸Spokane, Washington, United States
Optimus Clinical Research
🇦🇺Kogarah, New South Wales, Australia
Centro de Investigaciones Medicas Tucuman
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Emeritus Research
🇦🇺Camberwell, Victoria, Australia
Ziekenhuisnetwerk Antwerpen Jan Palfijn (ZNA Jan Palfijn)
🇧🇪Merksem, Belgium
UMHAT "Sv.Ivan Rilski" EAD
🇧🇬Sofia, Bulgaria
DCC Sveti Georgi EOOD
🇧🇬Plovdiv, Bulgaria
MHAT Plovdiv AD
🇧🇬Plovdiv, Bulgaria
Hospital Pablo Tobon Uribe
🇨🇴Medellin, Antioquia, Colombia
Centro Integral de Reumatología del Caribe S.A.S - CIRCARIBE S.A.S
🇨🇴Barranquilla, Atlantico, Colombia
Bluecare Salud S.A.S Sede Centro Médico Integral Chicó MedPlus CRI
🇨🇴Bogota, Cundinamarca, Colombia
UZ Leuven
🇧🇪Leuven, Belgium
Peking Union Medical College Hospital
🇨🇳Beijing, China
Umhat Kanev Ad
🇧🇬Ruse, Bulgaria
Anhui Provincial Hospital
🇨🇳Hefei, Anhui, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
Fudan University Hua Shan Hospital
🇨🇳Shanghai, China
UMHAT "Sv. Ivan Rilski" EAD
🇧🇬Sofia, Bulgaria
Centre intégré de santé et de services sociaux du Bas-Saint-Laurent
🇨🇦Rimouski, Quebec, Canada
Centre de Recherche Musculo-Squelettique
🇨🇦Trois-Rivieres, Quebec, Canada
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
The First Affiliated Hospital of Soochow University
🇨🇳Suzhou, Jiangsu, China
Centro de Investigación en Reumatología y Especialidades Médicas SAS - CIREEM SAS
🇨🇴Bogotá, Cundinamarca, Colombia
Ruijin Hospital- Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, China
Medicity S.A.S.
🇨🇴Bucaramanga, Santander, Colombia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Nemocnicni lekarna VFN
🇨🇿Praha 2, Czechia
Revmatologicky ustav
🇨🇿Praha 2, Czechia
Hôpital Pitié Salpêtrière, Centre des Maladies Auto-immunes
🇫🇷Paris, France
Hôpital Cochin
🇫🇷Paris, France
CHU de Bordeaux, Groupe Hospitalier Sud, Hôpital Haut Lévèque
🇫🇷Pessac, France
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Universitätsklinikum Schleswig Holstein - Campus Lübeck
🇩🇪Lübeck, Germany
University General Hospital of Heraklion
🇬🇷Heraklion, Crete, Greece
Laiko General Hospital, University of Athens
🇬🇷Athens, Greece
Qualiclinic Kft.
🇭🇺Budapest, Hungary
University Hospital ATTIKON
🇬🇷Haidari, Greece
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Békés Vármegyei Központi Kórház
🇭🇺Gyula, Hungary
Fondazione IRCCS Policlinico S.Matteo
🇮🇹Pavia, Italy
National Hospital Organization Asahikawa Medical Center
🇯🇵Asahikawa, Hokkaido, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Tohoku University Hospital
🇯🇵Sendai, Miyagi, Japan
Sasebo Chuo Hospital
🇯🇵Sasebo, Nagasaki, Japan
Shinkenko clinic
🇯🇵Naha, Okinawa, Japan
St. Luke's International Hospital
🇯🇵Chuo-ku, Tokyo, Japan
National Hospital Organization Chiba-East Hospital
🇯🇵Chiba, Japan
National Hospital Organization Kyushu Medical Center
🇯🇵Fukuoka, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
The Catholic Univ. of Korea Seoul St. Mary's Hospital
🇰🇷Seocho-gu, Seoul, Korea, Republic of
Morales Vargas Centro de Investigación S.C.
🇲🇽León, Guanajuato, Mexico
Kyungpook National University Hospital (KNUH)
🇰🇷Daegu, Korea, Republic of
CITER Centro de Investigación y Tratamiento de las Enfermedades Reumáticas S.A. de C.V.
🇲🇽Mexico City, Cuauhtémoc, Mexico
Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V
🇲🇽Guadalajara, Mexico
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
🇲🇽Mexico City, Tlalpan, Mexico
Investigación y Biomedicina de Chihuahua, Sociedad Civil
🇲🇽Chihuahua, Mexico
CINTRE Centro de Investigación y Tratamiento Reumatológico S.C.
🇲🇽Mexico City, Mexico
Szpital Biziela
🇵🇱Bydgoszcz, Poland
Centrum Wsparcia Badan Klinicznych
🇵🇱Warszawa, Mazowieckie, Poland
Stanislaw Sierakowski Centrum Miriada
🇵🇱Bialystok, Poland
Zespol Poradni Specjalistycznych Reumed, Onyksowa Filia nr 2
🇵🇱Lublin, Poland
NZOZ "Lecznica Mak-Med" s.c.
🇵🇱Nadarzyn, Poland
Centrum Medyczne MEDENS S.C. Grupowa Praktyka Lekarska
🇵🇱Sosnowiec, Poland
Hospital Garcia de Orta, E.P.E
🇵🇹Almada, Portugal
Hospital Professor Doutor Fernando da Fonseca, E.P.E
🇵🇹Amadora, Portugal
Unidade Local de Saude do Alto Minho, E.P.E.
🇵🇹Ponte de Lima, Portugal
Centro Hospitalar Universitario do Porto, E.P.E
🇵🇹Porto, Portugal
SC Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL
🇷🇴Brasov, JUD. Brasov, Romania
Spitalul Clinic Judetean de Urgenta Cluj-Napoca
🇷🇴Cluj-Napoca, Jud. Cluj, Romania
S.C. Euroclinic Hospital S.A
🇷🇴Bucuresti, Sector 1, Romania
Narodowy Instytutu Geriatrii, Reumatologii i Rehabilitacji
🇵🇱Warszawa, Poland
Mazowieckie Centrum Reumatologii i Osteoporozy M. Przygodzka Spolka jawna
🇵🇱Warszawa, Poland
Spitalul Clinic Sf. Maria
🇷🇴Bucuresti, Romania
Institut za Reumatologiju
🇷🇸Beograd, Serbia
Klinicki Centar Srbije, Klinika za alergologiju i imunologiju
🇷🇸Beograd, Serbia
Hospital do Meixoeiro
🇪🇸Vigo, Pontevedra, Spain
Institut Niska Banja, Klinika za Reumatologiju
🇷🇸Niska Banja, Serbia
Vojnomedicinska akademija, Klinika za reumatologiju
🇷🇸Beograd, Serbia
Hospital Germans Trias i Pujol
🇪🇸Badalona, Spain
Clinica Sagrada Familia
🇪🇸Barcelona, Spain
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
Complexo Hospitalario Universitario A Coruna
🇪🇸La Coruna, Spain
Hospital Quiron Infanta Luisa
🇪🇸Sevilla, Spain
China Medical University Hospital
🇨🇳Taichung City, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Kaohsiung Veterans General Hospital
🇨🇳Kaohsiung City, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital Linkou Branch
🇨🇳Taoyuan City, Taiwan
State Institution National Scientific Center "M.D. Strazhesko Institute of Cardiology"
🇺🇦Kyiv, Ukraine
Communal non-profitable enterprise "Lviv City Clinical Hospital #4"
🇺🇦Lviv, Ukraine
Multifield Medical Center of Odessa National Medical University
🇺🇦Odesa, Ukraine
CNPE "Odesa Regional Clinical Hospital" of Odesa Regional Council
🇺🇦Odesa, Ukraine
CNPE "Ternopil University Hospital" of Ternopil regional council, Department of Rheumatology
🇺🇦Ternopil, Ukraine
Zakarpattia Regional Clinical Hospital n.a. A. Novak
🇺🇦Uzhgorod, Ukraine
CNPE "Vinnytsya regional Clinical Hospital named after N.I.Pirogov Vinnytsia Regional Council"
🇺🇦Vinnytsia, Ukraine
Southampton General Hospital
🇬🇧Southampton, Hampshire, United Kingdom
Doncaster Royal Infirmary, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
🇬🇧Doncaster, United Kingdom
The Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital
🇬🇧Leeds, United Kingdom
Guy's and St Thomas' NHS Foundation Trust Guy's Hospital
🇬🇧London, United Kingdom
Omega Research MetroWest, LLC
🇺🇸Orlando, Florida, United States
Centro Peninsular de Investigación Clínica S.C.P.
🇲🇽Mérida, Yucatán, Mexico
Tekton Research
🇺🇸Austin, Texas, United States
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States
Tuen Mun Hospital
🇭🇰Hong Kong, Hong Kong